Sarepta Therapeutics (SRPT) Misses Q4 EPS by 7c, Revenue Misses

Sarepta Therapeutics (NASDAQ: SRPT) reported Q4 EPS of ($1.84), $0.07 worse than the analyst estimate of ($1.77). Revenue for the quarter came in at $122.6 million versus the consensus estimate of $146.3 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• Wolfe Research starts Ferrari at Outperform, sees 'solid upside potential'
• Unum Group (UNM) PT Raised to $94 at UBS on Second LTC Deal
• TRNR agrees to acquire STEPR, raises 2026 revenue guidance to $50M